| Diabetic retinopathy is an eye disorder that causes bleeding in the retina. Diabetic retinopathy is a microvascular complication of diabetes, which is chronic and progressive. Now, the disease has less attention due to its low prevalence, and it is hard to diagnosed. This is due to late diagnosis of clinical symptoms appear when the condition of bleeding in the retina have been troubling central vision patients. According world’s data, diabetic retinopathy causes blindness and vision loss. Based on its pathogenesis, diabetic retinopathy is caused by increased of Advanced Glication Endproducts (AGEs), activation of polyol pathway, activation of oxidative stress pathway, increased of Vascular Endothelial Growth Factor (VEGF), and increased of protein kinase-C. As the development of biotechnology, anti VEGF was developed progressively. VEGF is the key factor in retinal neovascularization and retinal hemorrhage. Anti-VEGF has some type to reduce neovascularization, it can be either VEGF or VEGF receptor itself, VEGF Trap-Eye, and VEGF aptamer. Administering anti-VEGF support to slow down progresivity of diabetic retinopathy. This scientific paper would discuss the effect of the anti-VEGF on diabetic retinopathy. |